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Background-—Aortic stenosis is the most common valvular disease and has a dismal prognosis without surgical treatment. The aim
of this meta-analysis was to quantitatively assess the comparative effectiveness of the Perceval (LivaNova) valve versus
conventional aortic bioprostheses.
Methods and Results-—A total of 6 comparative studies were identiﬁed, including 639 and 760 patients who underwent,
respectively, aortic valve replacement with the Perceval sutureless valve (P group) and with a conventional bioprosthesis (C group).
Aortic cross-clamping and cardiopulmonary bypass duration were signiﬁcantly lower in the P group. No difference in postoperative
mortality was shown for the P and C groups (2.8% versus 2.7%, respectively; odds ratio [OR]: 0.99 [95% conﬁdence interval (CI),
0.52–1.88]; P=0.98). Incidence of postoperative renal failure was lower in the P group compared with the C group (2.7% versus
5.5%; OR: 0.45 [95% CI, 0.25–0.80]; P=0.007). Incidence of stroke (2.3% versus 1.7%; OR: 1.34 [95% CI, 0.56–3.21]; P=0.51) and
paravalvular leak (3.1% versus 1.6%; OR: 2.52 [95% CI, 0.60–1.06]; P=0.21) was similar, whereas P group patients received fewer
blood transfusions than C group patients (1.161.2 versus 2.132.2; mean difference: 0.99 [95% CI, 1.22 to 0.75]; P=0.001).
The incidence of pacemaker implantation was higher in the P than the C group (7.9% versus 3.1%; OR: 2.45 [95% CI, 1.44–4.17];
P=0.001), whereas hemodynamic Perceval performance was better (transvalvular gradient 23.421.73 versus 22.81.86; mean
difference: 0.90 [95% CI, 0.62–1.18]; P=0.001), even during follow-up (10.985.7 versus 13.066.2; mean difference: 2.08
[95% CI, 3.96 to 0.21]; P=0.030). We found no difference in 1-year mortality.
Conclusions-—The Perceval bioprosthesis improves the postoperative course compared with conventional bioprostheses and is an
option for high-risk patients. ( J Am Heart Assoc. 2018;7:e006091. DOI: 10.1161/JAHA.117.006091.)
Key Words: aortic stenosis • prosthetic heart valve • Sutureless bioprothesis • Perceval valve
A ortic valve stenosis is the most common valve diseaseand results in poor outcomes without surgical treatment
for severe and symptomatic cases.1 In these patients, aortic
valve replacement is the treatment of choice. New implanta-
tion techniques have been developed to minimize the surgical
risk in older patients with multiple comorbidities.2
Sutureless technology has shown promising results in
terms of mortality, morbidity, and hemodynamic performance.
The Perceval S (LivaNova) sutureless aortic valve is a
collapsible, stent-mounted, aortic valve bioprosthesis that
can be placed in a sutureless fashion using a conventional
surgical technique with cardiopulmonary bypass (CPB), aortic
cross-clamping (ACC), and aortotomy, allowing complete
removal of the diseased native valve.
Several studies have shown that sutureless valves decrease
the CPB and ACC times, facilitating minimally invasive cardiac
surgery,3 but few studies compared this technology with
conventional stented valves. To our knowledge, no randomized
controlled trials have directly compared patients treated with
traditional and Perceval S valve bioprostheses.
The aim of this meta-analysis was to assess the compar-
ative effectiveness of Perceval and conventional
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bioprostheses, evaluating the current, best available evidence
from recent observational studies.
Methods
Data Sources and Search Strategy
We performed a systematic review and meta-analysis in
accordance with the standards set forth by the PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement.
We searched PubMed, Embase, and the Cochrane Collab-
oration databases using the following keywords: sutureless,
AND aortic valve, bioprosthesis AND aortic valve, rapid
deployment AND aortic valve, aortic valve AND surgery, OR
operation OR replacement. In addition, we hand-searched
references of retrieved articles and used related article
features in PubMed to identify studies not captured by our
primary search strategy. The search was limited to trials
involving human subjects, without language restriction. The
last search was performed December 31, 2016.
We included studies comparing the Perceval aortic valve
with conventional bioprostheses. Included studies contained
data on 30-day all-cause mortality and the outcomes
described in the Valve Academic Research Consortium
standardized end point deﬁnition.4,5
Once full articles were retrieved, studies were further
excluded if there was an overlap of patients with another
study within the same analysis (in such cases, the larger
sample size of the 2 studies was selected). Although some
patients could have been included in both the controlled and
uncontrolled study analyses, they were included only once in
any given analysis. Consequently, there was no overlap
among patients included in our meta-analyses.
Two reviewers (M.M. and A.M.) evaluated each article
separately.6 No disagreements occurred during the study-
selection process. A possible disagreement would have been
resolved by discussion with a third author (M.G.).
The study quality was examined using the method
recommended by a Cochrane Collaboration tool for assessing
risk of bias in the included studies. We extracted data
pertaining to baseline characteristics of study participants,
trial inclusion and exclusion criteria, postoperative complica-
tions, maximal length of follow-up, and mortality.
The primary end point was 30-day all-cause mortality.
Secondary end points were (1) CPB time, (2) ACC time, (3)
postoperative acute kidney injury (AKI), (4) postoperative
stroke, (5) postoperative transvalvular mean gradient, (6)
postoperative paravalvular leak, (7) postoperative pacemaker
implantation, and (8) 1-year mortality.
The present meta-analysis was conducted to analyze any
difference in mortality between aortic valve replacement with
the Perceval S valve (P group) and a conventional biopros-
thesis (C group).
The results from all relevant studies were combined to
estimate the odds ratios (ORs) and associated 95% conﬁ-
dence intervals (CIs) for dichotomous outcomes. With respect
to the continuous outcomes, weighted mean differences and
95% CIs were estimated as the effect results. Heterogeneity
was tested using the I2 statistic, and studies were classiﬁed
as having low (I2: 25–49%), moderate (I2: 50–74%), or high
(I2 ≥75%) heterogeneity. An I2 ≥50% indicates signiﬁcant
heterogeneity. In such cases, a random-effect model was
used, whereas an inverse variance method was used with the
ﬁxed-effect model when the outcome had no signiﬁcant
heterogeneity (I2 <50%). Whenever heterogeneity was pre-
sent, we performed sensitivity analyses to investigate the
inﬂuence of a single study by excluding 1 study in each turn.
Publication bias was assessed by funnel plot using mortality
as an end point. P<0.05 was considered statistically signif-
icant in this meta-analysis.
To evaluate the effect of preoperative parameters on the
incidence of postoperative AKI, we performed mixed-effects
(unrestricted maximum likelihood) metaregression analyses.
The metaregression graph depicts the percentages of
Perceval valves in the 2 groups, plotted as a logarithmic OR
on the y-axis and as a percentage of patients undergoing
Perceval implantation. The metaregression coefﬁcient (slope
of the metaregression line) shows the estimated increase in
logarithmic OR per unit increase in the covariate.
Because a logarithmic OR >0 corresponds to an OR >1 and
a logarithmic OR <0 corresponds to an OR <1, a negative
coefﬁcient would indicate that as a given factor (percentages
of patients in the groups undergoing Perceval implantation)
increases, the OR decreases; that is, Perceval is more
beneﬁcial in reducing the outcome of interest.
All analyses were conducted using Review Manager 5.1
software (Nordic Cochrane Centre) and Open Meta Analyst.6
Kaplan–Meier curves were digitized using a dedicated
software (Plot Digitizer; Free Software Foundation Europe).
Clinical Perspective
What Is New?
• The implantation of a Perceval (LivaNova) sutureless aortic
valve is associated with a better postoperative course, as
demonstrated by the lower incidence of postoperative renal
failure and blood transfusions.
What Are the Clinical Implications?
• The Perceval valve is a supportive option for high-risk
patients and for those at risk of patient–prosthesis
mismatch.
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With this tool, the axes were deﬁned, then the curve was read
point by point. The Kaplan–Meier data reconstruction was
used to derive individual patient data. We measured the
recurrence rate, which is a type of time-to-event data, with a
hazard ratio and 95% CI. Referring to Tierney et al,7 multiple
forms of published hazard ratio data, which may present as a
number of recurrence, as a Kaplan–Meier curve, or as another
form, were processed as observed–expected events research
(shown as O-E) and variance (shown as V). We analyzed the
transformed data in Revman 5.2 (Cochrane Collaboration). We
used the exponential [(O-E)/V] method to calculate hazard
ratios and to implement a time-to-event data analysis with a
ﬁxed-effect model.
Results
The study selection process is shown in Figure 1. After
exclusion of duplicate or irrelevant references, 114 potentially
relevant articles were retrieved. After detailed evaluation, 6
comparative studies8–13 met the inclusion criteria and were
considered in the present meta-analysis. A total of 1399
patients were included, of whom 639 underwent aortic valve
replacement with the Perceval sutureless valve (P group) and
760 received a conventional bioprosthesis (C group). The list
of included studies and the quality assessment for each study
is presented in Table S1 and Figure S1.
Preoperative characteristics are shown in Table 1. The
preoperative risk, calculated using the logistic EuroSCORE I,
was comparable between the 2 groups. The percentage of
patients with diabetes mellitus was signiﬁcantly higher in the
P group. No other preoperative differences were observed
between groups.
Postoperative Outcomes
All postoperative data are reported in Table 2. Meta-analysis
of the data showed that the pooled postoperative CPB
(67.420.2 versus 93.225.8 minutes for the P and C
groups, respectively; P=0.001) and ACC times (39.614.2
versus 6617.4 minutes for the P and C group, respectively;
P=0.001,) were signiﬁcantly lower in the P group.
Five studies8–12 reported the incidence of postoperative
AKI, and meta-analysis of the data showed that the pooled
postoperative AKI in the P group was signiﬁcantly lower
compared with the C group (Figure 2A). The patients in the P
group had less need for blood transfusions.
The incidence of postoperative respiratory failure was
similar in both groups, whereas the duration of mechanical
ventilation was signiﬁcantly less in the P group (Figure 2B).
The incidence of postoperative pacemaker implantation for
atrioventricular block was signiﬁcantly higher in the P group
(Figure 3A), whereas we found no difference in the incidence
of postoperative stroke (Table 2) and paravalvular leak
(Figure 3B) between groups.
Prosthesis size was signiﬁcantly larger and the postoper-
ative mean transvalvular gradient was signiﬁcantly lower in
the P group (Figure 3C).
Patients who underwent Perceval valve implantation were
more likely to receive a minimally invasive cardiac surgery
approach. There was no difference in postoperative mortality
between groups (Figure 4A).
Follow-up Data
All follow-up data at 1 year are reported in Figure 4B. Mean
follow-up of the patients in the P and C groups was
Figure 1. Study selection process.
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18.25+10.5 and 38.3+13.1 months, respectively. One-year
survival was 95.5+1.6% in the P group and 95.5+1.1% in the C
group, without signiﬁcant differences between groups.
The mean transvalvular gradient remained lower in
sutureless valves, even during follow-up, without reaching
statistical signiﬁcance (12.36.2 versus 13.27.1 mm Hg;
mean difference: 1.14; [95% CI, 2.79 to 0.50; P=0.18).
Inspection of the funnel plot (Figure S2) did not show
signiﬁcant asymmetry for all-cause mortality. Trim-and-ﬁll
analysis indicated that no studies were missing. These results
Table 1. Preoperative Characteristics of the Patients Included in the Meta-Analysis
P Group C Group OR/WMD† (95% CI) P Overall Effect
Logistic EuroSCORE 12.56.9 11.36.2 1.24 (0.48 to 2.87) 0.16
Age, y 77.74.6 75.95.9 1.45 (0.36 to 3.27) 0.12
Female, % 56 56 1.05 (0.83–1.33) 0.67
Diabetes mellitus, % 27.1 20.9 1.33 (1.01–1.75) 0.04*
Chronic renal failure, % 14.3 14.1 1.02 (0.72–1.43) 0.93
COPD, % 15.2 14.1 0.93 (0.67–1.51) 0.68
CAD, % 9.1 9.1 1.01 (0.66–1.51) 0.93
Cerebrovascular accidents, % 10.2 8.6 1.21 (0.81–1.82) 0.35
NYHA class 3/4, % 55.5 54.7 1.12 (0.82–1.52) 0.47
Hypertension, % 73.7 69.6 1.20 (0.88–1.63) 0.24
LVEF 57.28 56.87.6 0.11 (2.02 to 2.24) 0.92
Body mass index 27.74.9 26.94.4 0.08 (1.08 to 0.92) 0.88
CAD indicates coronary artery disease; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; LVEF, left ventricle ejection fraction; NYHA, New York Heart Association; OR,
odds ratio; WMD, weighted mean difference.
*Indicates statistically signiﬁcant.
†Data as percentage are odds ratios, mean values are weighted mean differences.
Table 2. Postoperative Results
P Group C Group OR/WMD† (95% CI) P Overall Effect
Minimally invasive, % 96.53 43.86 301 (112–805) 0.001*
30-d mortality, % 2.8 2.7 0.99 (0.52–1.88) 0.980
Renal failure, % 2.7 5.5 0.45 (0.25–0.80) 0.007*
Respiratory failure, % 5.4 6.8 0.83 (0.45–1.52) 0.540
Stroke, % 2.3 1.7 1.34 (0.56–3.21) 0.510
Pacemaker, % 7.9 3.1 2.45 (1.44–4.17) 0.001*
Paravalvular leak, % 3.1 1.6 2.52 (0.60–1.06) 0.210
Blood transfusions 1.16+1.2 2.13+2.2 0.99 (1.22 to 0.75) 0.001*
CPB time, min 67.4+20.2 93.2+25.8 25.28 (32.0 to 18.4) 0.001*
ACC time, min 39.6+14.2 66+17.4 26.26 (30 to 22.48) 0.001*
Mechanical ventilation time, h 7.62.3 117.5 1.05 (1.43 to 0.67) 0.001*
ICU stay, d 1.71.5 1.92.2 0.2 (0.66–0.25) 0.38
Transfused RBCs, U 3.53.8 6.46.7 0.99 (1.22 to 0.75 0.001*
Prosthesis size, mm 23.42+1.73 22.8+1.86 0.90 (0.62–1.18) 0.001*
Mean gradient, mm Hg 10.98+5.7 13.06+6.2 2.08 (3.96 to 0.21) 0.030*
ACC indicates aortic cross-clamping; CI, conﬁdence interval; CPB, cardiopulmonary bypass; ICU, intensive care unit; OR, odds ratio; RBCs, red blood cells; WMD, weighted mean difference.
*Indicates statistically signiﬁcant.
†Data as percentage are odds ratios, mean values are weighted mean differences.
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suggest that publication bias was not a signiﬁcantly inﬂuenc-
ing factor.
Discussion
This meta-analysis showed that the Perceval sutureless
bioprosthesis is safe. The use of the Perceval valve reduced
CPB and ACC times and the amount of blood transfused and
showed lower incidence of postoperative AKI. Moreover, the
use of the Perceval valve allowed for implantation of larger
diameter prostheses, resulting in lower transvalvular gradient,
and there was no difference in the frequency of postoperative
strokes and paravalvular leaks between groups.
The incidence of postoperative pacemaker implantation
was signiﬁcantly higher in the P group. The incidence of
permanent pacemaker implantation after aortic valve replace-
ment with conventional bioprostheses is reported to be highly
variable, ranging between 3% and 8.5%.14,15
Many preoperative and intraoperative factors contribute to
the ﬁnal result. Preoperative right or left bundle-branch block
and ﬁrst-degree atrioventricular block were identiﬁed as
important risk factors for the development of postoperative
conduction disturbances.17 Moreover, the conduction tissue
may be directly damaged by extensive annular debridement.17
Vogt et al8 reported a high incidence (10.5%) of postop-
erative pacemaker implantation after Perceval valve implan-
tation and identiﬁed only preoperative right bundle-branch
block as a risk factor but showed high variability in the rates
of postoperative pacemaker implantation for the 2 surgeons
who performed the operations. This factor suggests the key
role of the surgeon’s technique and experience in inﬂuencing
this complication.
Moreover, the large intra-annular sealing coil of the
Perceval bioprosthesis may be the cause of atrioventricular
conduction disorders because the prosthesis frame delivers
an outward force that affects the aortic annulus during
balloon dilatation.18 To overcome this issue, Yanagawa et al
described a simple modiﬁcation of the surgical technique,
placing the guiding sutures at the nadir of each cusp and not
2 or 3 mm below.16 This technique allows for targeting
postoperative permanent pacemaker implantation in their
cohort. The positioning of the Perceval valve some millime-
ters lower than the aortic annulus may cause the compres-
sion of the conduction system by the nitinol stent, causing
atrioventricular block.19 None of the studies included in this
meta-analysis reported the presence of preoperative con-
duction disturbances or quantiﬁed preoperative aortic annu-
lar calciﬁcation; therefore, we could not know whether
patients in the P group had a higher risk of pacemaker
implantation.
Despite signiﬁcant technical improvements over time, CPB
remains a crucial factor in determining postoperative morbid-
ity and mortality. Contact of blood components with the
artiﬁcial surface of the bypass circuit causes a systemic
inﬂammatory response syndrome associated with CPB,17
resulting in diffuse microcirculatory damage leading to
postoperative organ dysfunction. Many factors, including
CPB duration, have been associated with AKI after cardiac
surgery. The impact of AKI on poor outcomes after cardiac
surgery is remarkable, especially if it leads to continuous renal
Figure 2. Forrest plot of the odds ratio or mean difference of (A) acute kidney injury and (B) length of mechanical ventilation after Perceval
valve vs conventional bioprosthesis implantation. CI indicates conﬁdence interval; IV, inverse variance; M-H, Mantel–Haenszel.
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replacement therapy.20 Several studies associated longer CPB
with postoperative AKI.21–23
Based on these premises, the lower frequency of postop-
erative AKI in the P group might be explained by a shorter
duration of CPB with Perceval valve implantation. However,
we have to consider that the study by Muneretto et al11 could
have inﬂuenced the incidence rate for postoperative AKI: This
study is the largest included in the meta-analysis, and the
authors reported very high incidence of postoperative AKI.
This fact could be explained by the large number of patients at
increased risk for postoperative complications, as explained
by the high mean EuroSCORE.
In the Perceval group, we reported a lower duration of CPB.
CPB is associated with impaired hemostatic function in the
mechanisms of hemodilution, activation,24,25 and consump-
tion.26 Moreover, CPB duration is signiﬁcantly associated with
postoperative nonsurgical bleeding27 and increased
transfusion of blood products28—well-known risk factors for
postoperative morbidity and mortality in cardiac surgery.29
The lower CPB time may at least partly explain the lower
amount of postoperative transfusion of blood products.
Our meta-analysis showed that implantation of a Perceval
valve increases the likelihood that the surgery will be
performed with a minimally invasive approach. In fact, our
meta-analysis showed that the percentage of patients under-
going minimally invasive surgery was signiﬁcantly higher in
the P group, but this ﬁnding is not straightforward. Indeed, the
variability of minimally invasive procedures within groups is
very high, between 0% to 100%, suggesting that the choice of
a minimally invasive approach is inﬂuenced by the habits and
experience of the surgeon.
It is still under discussion whether the minimally invasive
aortic valve replacement surgery could signiﬁcantly inﬂuence
strong outcomes. Two large meta-analyses30,31 showed
Figure 3. Forrest plot of the odds ratio or mean difference of (A) postoperative pacemaker implantation, (B) paravalvular leak, and (C) mean
transvalvular gradient after Perceval valve vs conventional bioprosthesis implantation. CI indicates conﬁdence interval; IV, inverse variance; M-H,
Mantel–Haenszel.
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shorter intensive care unit and hospital stays for patients who
underwent minimally invasive aortic valve replacement com-
pared with conventional surgery, but both studies reported
longer CPB and ACC times for the minimally invasive
approach.
Moreover, all studies comparing the minimally invasive and
conventional approaches reported a signiﬁcant increase in CPB
times when conventional valves were implanted.32 Conse-
quently, it seems reasonable to argue that the increase in CPB
time could mask, in some way, the potential advantages of
minimally invasive cardiac surgery, especially in high-risk
patients who would beneﬁt from a minor surgical insult.
Dalen et al9 and Miceli et al33 showed that the use of the
Perceval valve in minimally invasive aortic valve replacement
is associated with a signiﬁcant decrease in CPB time
compared with conventional valves. Therefore, the ease of
implantation and the consequent reduction of the CPB time
could make the Perceval valve the ﬁrst choice for high-risk
patients undergoing minimally invasive cardiac surgery.
This meta-analysis showed that the use of Perceval valve
allowed the implantation of valves of greater diameter with
better hemodynamic performance (as indicated by the lower
transvalvular gradient). The conventional valves have a sewing
ring, and, for any given valve size, at least some part of the
external valve area is taken up by this sewing ring. This may
lead to patient–prosthesis mismatch, particularly in patients
with small aortic roots. Incidence of prosthesis–patient
mismatch ranges between 2% and 11% after aortic valve
replacement and leads to lack of regression of left ventricular
hypertrophy,34 persistent symptoms, and reduced survival.33
Implantation of the Perceval valve may a viable alternative for
patients who need conventional aortic root enlargement to
treat a small aortic annulus and to avoid patient–prosthesis
mismatch, especially in older patients, who typically beneﬁt
from the quick implantation process.35 Sutureless valves have
been proposed recently as an ideal solution for this subset of
patients13: Given the absence of a sewing ring, these valves
are almost “stentless,” with a greater valve effective oriﬁce
area for any given size.
Our meta-analysis did not show any mortality beneﬁt for
patients who underwent implantation of the Perceval valve
versus conventional bioprostheses for aortic stenosis. How-
ever, the reduction of blood transfusions, the lower incidence
of postoperative AKI, and the better hemodynamic proﬁle of
the Perceval valve make it an option worth considering for
patients at high operative risk and at risk of patient–
prosthesis mismatch. Randomized controlled trials are war-
ranted to expand reliable evidence in this ﬁeld, ensuring
appropriate selection of the aortic prosthesis on the basis of
each patient’s characteristics.
Limitations of this meta-analysis merit careful considera-
tion. There were few trials, and the absence of randomized
controlled trials comparing sutureless and conventional
bioprostheses represents the main limitation of our meta-
analysis. Three studies used a propensity score matching
technique. Despite the absence of overt biases, we cannot
consider these studies equivalent to randomized controlled
trials; therefore, the results should be interpreted carefully
when they are included in systematic reviews and meta-
analysis. Particular concerns arise with respect to differences
Figure 4. Forrest plot of the Peto odds ratio of (A) postoperative mortality, of (B) 1-year survival. CI indicates conﬁdence interval; O-E,
observed–expected events; V, variance; Exp, exponential
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between patients in different intervention groups (selection
bias) and studies that did not explicitly report a protocol
(reporting bias). Unlike randomized trials, it would usually be
appropriate to analyze adjusted, rather than unadjusted,
effect estimates (ie, analyses that attempt to control for
confounding). To reduce the effect of treatment selection bias
and potential confounding in observational studies, rigorous
adjustment for signiﬁcant differences in patients’ baseline
characteristics should be conducted. Furthermore, adjusted
estimates have to be pooled in a meta-analysis that includes
observational studies. In the present meta-analysis, we strictly
selected and then included only adjusted ORs or hazard ratios
for all-cause mortality, using appropriate statistical methods
from observational studies. Our results may be inﬂuenced by
a publication bias favoring sutureless valve. This risk was
minimized through an exhaustive search of the available
literature in our analysis. Because the statistical tests did not
indicate publication bias, there is limited power to detect such
bias, given the small number of studies examined.
Conclusions
The Perceval bioprostheis ensures a better postoperative
course than coventional bioprostheses and deserves con-
sideration in patients at high surgical risk. Future RCTs are
required to enlight its possible role in reducing mortality.
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SUPPLEMENTAL MATERIAL 
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Table S1. List of included studies 
 
PSM: propensity score match; POS: prospective observational study, RS: retrospective study
First author Year Institution Study period Type of 
study 
Type of SU Number 
SU 
Number 
AVR 
Mean follow up 
SU (years) 
Mean follow up AVR 
(years) 
Muneretto[1] 2014 University of Brescia, 
Italy 
October 2010 to 
February 2013 
PSM Perceval S 204 204 1.9+0.6 2+0.8 
Gilmanov[2] 2014 Pasquinucci Hospital, 
Massa, Italy 
August 2004 to 
January 2014 
PSM Perceval S 133 133 1.5+0.6 4.5+1.5 
Dalen[3] 2015 Six European Centers 
June 2007 to April 
2014 
PSM Perceval S 171 171 2.7+2.1 4.2+1.7 
Santarpino[4] 2013 Klinicum Nurnberg, 
Nuremberg, Germany 
March 2010 to 
December 2011 
POS Perceval S 50 50 none none 
D’Onofrio[5] 2012 Three Italian Centers 
March 2011 to 
September 2011 
PSM Perceval S 31 112 none none 
Shrestha[6] 2013 Hannover Medical 
school, Germany 
April 2007 to 
December 2012 
RS Perceval S 50 70 1.8+1.4 2.6+1.3 
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Figure S1. Risk of bias summary: review authors' judgements about each risk of bias item for included study. 
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Figure S2. Funnel plot for the meta analysis of the mortality of Perceval valve compared with conventional 
prosthesis.
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